您的当前位置:首页 > 行业数据 > 百奥赛图人源化小鼠可用于多种类型新药开发临床前研究
图片属性
图片格式:PNG 图片大小:898KB 图片尺寸:2310*1362
同报告图片
 / 4
百奥赛图人源化小鼠可用于多种类型新药开发临床前研究_第1页
fCDoja/niakv55aX5rOV57G75Z6LICAgICAgIHwg5pWw6YePICAgfCDlhbfkvZPlhoXlrrkgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwKfC0tLS0tLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tfAp8IOaKl+S9k+iNr++8iOWNleaKl++8jOWPjOaKl++8iSB8IDcwMCsgICB8IFBELTHjgIE0LTFCQuOAgUNEM0XjgIFDRDE2QeOAgUNDUjjjgIFOS0cyQeOAgU5LRzJE44CBSUw0UuOAgVRTTFDjgIFJTDE3QS9G44CBVEwxQeOAgUlMMjMgfAp8IENBUiAtIFTnu4bog57msrvnlpcgICAgIHwgNTArICAgIHwgQiAtIE5ER+OAgUIgLSBOREcgaElMMTXjgIFCIC0gTkRHIEdMM+OAgUIgLSBOREcgTUhDIEkvSUkgREtP44CBQiAtIE5ERyBLaXQgVzQxIG1pY2XjgIFCIC0gTkRHIEZDzrNSIEtPIG1pY2UgfAp8IOaguOmFuOexu+iNr+eJqSAgICAgICAgIHwgMTAwKyAgIHwgQU5HUFRMM+OAgVBDU0s544CBTFBB44CBQUdU44CBQVBPQzPjgIFDRkLjgIFHTFAxUuOAgUhTRDE3QjPjgIFJTkhCRSAgICAgICAgICAgICAgIHwKfCDmipfkvZPoja/nianlgbbogZTnianvvIhBREPvvIkgfCAyMDArICAgfCBIRVIy44CBVFJPUDLjgIFFR0ZS44CBQjcgLSBIM+OAgUNEMjDjgIFDRDE544CBRExMM+OAgU5FRlRJTjTjgIFHUEMz44CBNVQ044CBQ0RIMTfjgIFFUENBTSB8Cnwg55ar6IuXICAgICAgICAgICAgICAgfCA1MCsgICAgfCBITEEgLSAyLjHjgIFITEEgLSAxMS4x44CBSExBIC0gMjQuMuOAgUhMQSAtIDMuMeOAgUhMQSAtIEIzNS4x44CBSExBIC0gQjcuMuOAgUhMQSAtIERSMeOAgUhMQSAtIERSNCB8CgrotYTmlpnmnaXmupDvvJrnmb7lpaXotZvlm77lrpjnvZHvvIzlm73ogZTmsJHnlJ/or4HliLjnoJTnqbbmiYA=
百奥赛图人源化小鼠可用于多种类型新药开发临床前研究_第2页
百奥赛图人源化小鼠可用于多种类型新药开发临床前研究_第3页
百奥赛图人源化小鼠可用于多种类型新药开发临床前研究_第4页
百奥赛图人源化小鼠可用于多种类型新药开发临床前研究_第5页
所属报告: 百奥赛图(2315.HK)-港股公司首次覆盖报告:赋能全球新药研发基石业务稳增长抗体平台高弹性-260103(40页).pdf
打包全文图表

相关数据

客服
商务合作
小程序
服务号
折叠